Kadimastem
Stem Cell Therapeutics for Diabetes and ALS
StartupKadimastem is a Ness Ziona-based startup in the Health Tech & Life Sciences sector, established in 2008. Stem Cell Therapeutics for Diabetes and ALS. The company has raised a total of $45.35M across 9 funding rounds, currently at the Mature stage. Kadimastem was founded by Michel Revel. Key investors include Ilex Medical, Clover Wolf Capital, Alpha Capital Anstalt, among 11 total investors. The company has 11-50 employees. Core technologies: Biologicals, Cells.
With $45.35M in total funding, Kadimastem is a Mature-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageMature
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQNess Ziona
- DistrictCenter District
- Last Round$882K
- Ilex Medical
- Clover Wolf CapitalLead
- Alpha Capital Anstalt
11 investors total
Michel RevelCo-Founder, VP R&D
76 articles covered by sources including www.prnewswire.com,
finance.yahoo.com,
www.abc4.com,
newsdirect.com,
en.globes.co.il.
What does Kadimastem do?
Kadimastem develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as amyotrophic lateral sclerosis (ALS) and diabetes. The technology has been developed as a platform enabling the manufacture of islet-like endocrine cells and glia-restricted progenitors. It has potential applications for diabetes and neurodegenerative diseases such as ALS. The therapy is scalable, industrialized, and will be commercialized as a stable off-the-shelf product to reduce the cost of treatments. For its technology, Kadimastem uses pluripotent cells that can multiply infinitely without losing their naive state or ability to become any cell type. The product is produced under GMP guidelines (similar to traditional therapeutics) in order to reach optimal medical results. The company's process differentiates the cells in the lab, before their injection into the patient. The company's process markedly enhances the efficiency of the treatment.
How much funding has Kadimastem raised?
Kadimastem has raised $45.35M in total funding across 9 rounds. The company is currently at the Mature stage. Key investors include Ilex Medical, Clover Wolf Capital, Alpha Capital Anstalt.
Who founded Kadimastem?
Kadimastem was founded in 2008 by Michel Revel (Co-Founder, VP R&D ).
What sector is Kadimastem in?
Kadimastem operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Kadimastem located?
Kadimastem is based in Pinhas Sapir St 7, Ness Ziyyona, Israel, Center District.